Neurologic complications of infectious mononucleosis

Connelly, Kevin P.; DeWitt, L. D.

doi:10.1016/0887-8994(94)90021-3

Cited by 106 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 2 lists the complications whose frequency is estimated to be at least 1%. The following complications, listed alphabetically, have been described for fewer than 1% of patients: conjunctivitis, hemophagocytic syndrome, myocarditis, neurologic diseases other than meningoencephalitis, pancreatitis, parotitis, pericarditis, pneumonitis, psychological disorders, and splenic rupture (38,87,102,171,215). Splenic rupture is a rare but greatly feared complication that excludes athletes from contact sports for various periods (see "Limitation of activities").…”

Section: Infectious Mononucleosismentioning

confidence: 99%

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

2011

View full text Add to dashboard Cite

SUMMARY Epstein-Barr virus (EBV) is a gammaherpesvirus that infects a large fraction of the human population. Primary infection is often asymptomatic but results in lifelong infection, which is kept in check by the host immune system. In some cases, primary infection can result in infectious mononucleosis. Furthermore, when host-virus balance is not achieved, the virus can drive potentially lethal lymphoproliferation and lymphomagenesis. In this review, we describe the biology of EBV and the host immune response. We review the diagnosis of EBV infection and discuss the characteristics and pathogenesis of infectious mononucleosis. These topics are approached in the context of developing therapeutic and preventative strategies.

show abstract

Section: Infectious Mononucleosismentioning

confidence: 99%

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

2011

View full text Add to dashboard Cite

show abstract

“…Most symptoms tend to disappear in 2 to 4 weeks, although complications, including neurological disorders, can occur. The incidence of neurologic complications from infectious mononucleosis in the literature range from 0.3 % to 7.3 % and include encephalitis, seizures, optic neuritis, facial palsy, and Guillain-Barré syndrome among others [31][32][33]. Although most of the neurologic complications from viral infections are acute, it is conceivable that a combination of the mutations in the susceptibility gene CACNA1H and the patient's viral infection combined triggered persistent changes in Cav3.2 channel function, thus giving rise to epilepsy and pain syndrome.…”

Section: Discussionmentioning

confidence: 99%

Two heterozygous Cav3.2 channel mutations in a pediatric chronic pain patient: recording condition-dependent biophysical effects

Souza

Gandini

Wan

et al. 2015

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

We report expression system-dependent effects of heterozygous mutations (P769L and A1059S) in the Cav3.2 CACNA1H gene identified in a pediatric patient with chronic pain and absence seizures. The mutations were introduced individually into recombinant channels and then analyzed by means of electrophysiology. When both mutants were coexpressed in tsA-201 cells, we observed a loss of channel function, with significantly smaller current densities across a wide range of voltages (−40 to +20 mV). In addition, when both mutant channels were co-expressed, the channels opened at a more depolarizing potential with a~5-mV right shift in the half-activation potential, with no changes in half-inactivation potential and the rate of recovery from inactivation. Interestingly, when both mutants were co-expressed in the neuronalderived CAD cells in a different extracellular milieu, the effect was remarkably different. Although not statistically significant (p < 0.07), current densities appeared augmented compared to wild-type channels and the difference in the halfactivation potential was lost. This could be attributed to the replacement of extracellular sodium and potassium with tetraethylammonium chloride. Our results show that experimental conditions can be a confounding factor in the biophysical effects of T-type calcium channel mutations found in certain neurological disorders.

show abstract

“…A wide variety of neurologic presentations are also associated with Epstein-Barr virus (EBV), including Guillain-Barré syndrome, cranial nerve palsy, optic neuritis, encephalitis, and meningitis. Encephalitis/ meningitis was in fact the first described neurologic complication of infectious mononucleosis (IM), a symptomatic primary infection with EBV [55]. The frequency of neurologic involvement in IM is estimated around 1-18 %.…”

Section: Vaccines Under Development For Human Herpesvirusesmentioning

confidence: 99%

Vaccinations for Neuroinfectious Disease: A Global Health Priority

Leibovitch

Jacobson

2016

Neurotherapeutics

View full text Add to dashboard Cite

Vaccines for neuroinfectious diseases are becoming an ever-increasing global health priority, as neurologic manifestations and sequelae from existing and emerging central nervous system infections account for significant worldwide morbidity and mortality. The prevention of neurotropic infections can be achieved through globally coordinated vaccination campaigns, which have successfully eradicated nonzoonotic agents such as the variola viruses and, hopefully soon, poliovirus. This review discusses vaccines that are currently available or under development for zoonotic flaviviruses and alphaviruses, including Japanese and tick-borne encephalitis, yellow fever, West Nile, dengue, Zika, encephalitic equine viruses, and chikungunya. Also discussed are nonzoonotic agents, including measles and human herpesviruses, as well as select bacterial, fungal, and protozoal pathogens. While therapeutic vaccines will be required to treat a multitude of ongoing infections of the nervous system, the ideal vaccination strategy is preexposure vaccination, with the ultimate goals of minimizing disease associated with zoonotic viruses and the total eradication of nonzoonotic agents.

show abstract

Neurologic complications of infectious mononucleosis

Cited by 106 publications

References 35 publications

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

Two heterozygous Cav3.2 channel mutations in a pediatric chronic pain patient: recording condition-dependent biophysical effects

Vaccinations for Neuroinfectious Disease: A Global Health Priority

Contact Info

Product

Resources

About